|Bid||37.00 x 1300|
|Ask||361.09 x 1000|
|Day's Range||339.25 - 344.55|
|52 Week Range||226.02 - 373.90|
|Beta (3Y Monthly)||1.08|
|PE Ratio (TTM)||58.98|
|Earnings Date||Oct 30, 2019 - Nov 4, 2019|
|Forward Dividend & Yield||1.36 (0.40%)|
|1y Target Est||400.91|
Teleflex Incorporated (TFX) today announced the publication of an article showcasing the effectiveness and overall benefits of the minimally invasive UroLift® System treatment for patients with benign prostatic hyperplasia (BPH). The article, DeMISTifying less-invasive solutions for BPH, reviews the objectives of using minimally invasive surgical technologies (MIST) to treat BPH, and recommends useful metrics to measure the success of these treatments, including the UroLift System. The article, published in Urology Times, is authored by Steven Kaplan, M.D., professor of Urology, Icahn School of Medicine at Mount Sinai and director of the Men’s Health Program at Mount Sinai Health System, New York.
WAYNE, Pa., Sept. 13, 2019 -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, will focus on its Arrow® EZ-IO® Intraosseous Access System.
Executive Vice President & CFO of Teleflex Inc (30-Year Financial, Insider Trades) Thomas E Powell (insider trades) sold 7,500 shares of TFX on 09/06/2019 at an average price of $355.52 a share. Continue reading...
WAYNE, Pa., Aug. 30, 2019 -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, will showcase its Peripheral Intervention product portfolio.
WAYNE, Pa., Aug. 28, 2019 -- Liam Kelly, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the Morgan Stanley 17th Annual Global Healthcare.
How far off is Teleflex Incorporated (NYSE:TFX) from its intrinsic value? Using the most recent financial data, we'll...
WAYNE, Pa., Aug. 21, 2019 -- Liam Kelly, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the Wells Fargo Securities 2019 Healthcare Conference at.
Teleflex Incorporated (TFX) today announced the UroLift® System, a proven, minimally invasive treatment for patients with benign prostatic hyperplasia (BPH), won the 2019 James & Wells Medical Technology Association of New Zealand (MTANZ) Innovation Award at the Health Tech Week Gala on July 2. The MTANZ Innovation Award recognizes products that significantly contribute to improving patient outcomes by enhancing their quality of life, as well as exhibiting technical excellence and innovation across the entire medical device sector. Recipients for the MTANZ Innovation Award are determined by a judging panel consisting of distinguished industry leaders and clinicians.
Teleflex (TFX) delivered earnings and revenue surprises of 2.70% and 2.48%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
WAYNE, Pa., Aug. 01, 2019 -- Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per.
Second Quarter Revenues from Continuing Operations of $652.5 million, up 7% versus Prior Year Period; up 9.6% on a Constant Currency Basis Second Quarter GAAP Diluted EPS from.
WAYNE, Pa., Aug. 01, 2019 -- Teleflex Incorporated (NYSE: TFX) today announced the publication of the “Pivotal Clinical Study to Evaluate the Safety and Effectiveness of the.